Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 4, 1998, Pages 917-923

  Mattila, M J ^a   Vanakoski, J ^a   Kalska, H ^b   Seppala T ^c  

^a BIOMEDICUM HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Diazepam; Ethanol; Memory; Oxazepam; Performance; Plasma concentrations; Zolpidem; Zopiclone

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALCOHOL; BENZODIAZEPINE DERIVATIVE; DIAPAM; DIAZEPAM; OPAMOX; OXAZEPAM; SEDATIVE AGENT; UNCLASSIFIED DRUG; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY EQUILIBRIUM; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LEARNING; MALE; MEMORY CONSOLIDATION; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SEDATION;

ADULT; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOL; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MEMORY; MUSCULOSKELETAL EQUILIBRIUM; PSYCHOMOTOR PERFORMANCE; PYRIDINES; REACTION TIME;

EID: 0032052683     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00506-6     Document Type: Article

References (31)

1. Allain H., Patat A., Lieury A., Le Coz F., Janus C., Menard G., Gandon J. M. Comparative study of the effects of zopiclone, zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. Eur. Psychiatry. 10(Suppl. 3):1995;129s-135s.
2. Berlin I., Warot D., Hergueta T., Molinier P., Bagot C., Puech A. J. Comparison of the effects of zolpidem and triazolam on memory functions, and psychomotor performances, and postural sway in healthy subjects. J. Clin. Psychopharmacol. 13:1993;100-106.
3. Byrnes J. J., Greenblatt D. J., Miller L. G. Benzodiazepine receptor binding of nonbenzodiazepines in vivo in vivo. Alpidem, zolpidem and zopiclone Brain Res. Bull. 29:1992;905-908.
4. DeClerc A., Bisserbe J. C. Short-term safety profile of zolpidem. Objective measures of cognitive effects Eur. Psychiatry. 11(Suppl. 5):1996;459s-464s.
5. Doble A., Canton T., Malgouris C., Stutzmann J. M., Piot T., Bardone M. C., Pauchet C., Blanchard J. C. The mechanisms of action of zopiclone. Eur. Psychiatry. 10(Suppl. 3):1996;117s-128s.
6. Freeman H., Puech A. J., Roth T. Zolpidem. An update of its pharmacological properties and therapeutic place in the management of insomnia:1996;Elsevier, Paris.
7. Garnier R., Guerault E., Muzard D., Azoyan P., Chaumet-Riffaud A. E., Ethymiou M. L. Acute zolpidem poisoning-analysis of 344 cases. J. Toxicol. Clin. Toxicol. 32:1994;391-404.
8. Hindmarch I. Critical flicker fusion frequency (CFF). The effects of psychotropic compounds Pharmacopsychiatry. 15(Suppl. 1):1982;44-48.
9. Im H. K., Im W. B., Hamilton B. J., Carter D. B., Vonvoigtlander P. F. Potentiation of gamma-aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the alpha 1 gamma 2, beta 2 gamma 2 and alpha 1 beta 2 gamma1 subtypes of cloned gamma-aminobutyric acid type A receptors. Mol. Pharmacol. 44:1993;866-870.
10. Kuitunen T., Mattila M. J., Seppälä T., Aranko K., Mattila M. E. Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests. Br. J. Clin. Pharmacol. 30:1990;453-461.
11. Lader M. Zopiclone. Is there any dependence and abuse potential? J. Neurol. 244(Suppl 1):1997;S18-22.
12. Langer S. Z., Arbilla S. Imidazopyridines as a tool for the characterization of benzodiazepine receptors. A proposal for a pharmacological classification as omega receptor subtypes Pharmacol. Biochem. Behav. 29:1988;763-766.
13. Lillsunde P., Seppälä T. Simultaneous screening and quantitive analysis of benzodiazepines by dual-channel gas chromatography using electron-capture and nitrogen-phosphorus detection. J. Chromatogr. 533:1990;97-110.
14. Linnavuo M., Ylilääkkölä P., Mattila M. J., Mäki M., Seppälä T. A new device to measure drug-induced changes on reactive and coordinative skills of human performance. Pharmacol. Toxicol. 61:1987;142-147.
15. Lista A., Blier P., de Montigny C. Benzodieazepine receptors modulate 5-hydroxytryptamine neurotransmission in the rat hippocampus. In vivo electrophysiological evidence J. Pharmacol. Exp. Ther. 254:1990;318-323.
16. Lister R. G. The amnesic action of benzodiazepines in man. Neurosci. Biobehav. Rev. 9:1985;87-94.
17. A receptor subunits. Trends Pharmacol. Sci. 12:1991;49-51.
18. A/benzodiazepine receptor heterogeneity. Neurophysiological impact Neuropharmacology. 34:1995;245-254.
19. Mattila M. Acute and subacute effects of diazepam on human performance. Comparison of plain tablet and controlled release capsule Pharmacol. Toxicol. 63:1988;369-374.
20. Mattila M. J., Aranko K., Mattila M. E., Paakkari I. Effects of psychotropic drugs on digit substitution. Comparison of the computerized symbol-digit substitution and traditional digit-symbol substitution tests J. Psychopharmacol. 8:1994;81-87.
21. Mattila M. J., Mattila M. E., Olkkola K., Scheinin H. Effect of dexmedetomidine and midazolam on human performance and mood. Eur. J. Clin. Pharmacol. 41:1991;217-221.
22. Nicholson A. N. Performance studies with diazepam and its hydroxylated metabolites. Br. J. Clin. Pharmacol. 8:1979;39S-42S.
23. Pichard L., Gillet G., Bonfils C., Domerque J., Thenot J. P., Maurel P. Oxidative metabolism of zolpidem by human liver cytochrome P450. Drug Metab. Dispos. 23:1995;1253-1262.
24. 5-subunit creates novel type II benzodiazepine receptor pharmacology. J. Neurochem. 54:1990;1802-1804.
25. Roehrs T., Merlotti L., Zorick F., Roth T. Sedative, memory and performance effects of hypnotics. Psychopharmacology (Berlin). 116:1994;130-134.
26. Rush G. R., Griffiths R. R. Zolpidem, triazolam, and temazepam - Behavioral and subject-rated effects in normal volunteers. J. Clin. Psychopharmacol. 16:1996;146-157.
27. Salva P., Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications Clin. Pharmacokinet. 29:1995;142-153.
28. 3Hflumazenil binding in different regions of the rat nervous system Psychopharmacology (Berlin). 111:1993;315-322.
29. Schmid L., Bottlaender M., Fuseau C., Fournier D., Brouillet E., Maziere M. Zolpidem displays heterogeneity in its binding to the nonhuman primate benzodiazepine receptor in vivo. J. Neurochem. 65:1995;1880-1886.
30. Unden M., Roth Schechter B. Next day effects after nighttime with zolpidem. A review Eur. Psychiatry. 11(Suppl. 1):1996;21s-30s.
31. Wesensten N. J., Balkin T. J., Belenky G. L. Effects of daytime administration of zolpidem vs. triazolam on memory. Eur. J. Clin. Pharmacol. 48:1995;115-122.